+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Respiratory Drugs Market Global Briefing 2018

  • ID: 4452381
  • Report
  • Region: Global
  • 34 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Gilead
  • GlaxosmithKline Plc.
  • Johnson & Johnson
  • MORE
North America was the largest region in the respiratory diseases drugs market in 2017, accounting for around 48% market share. Asia Pacific was the second largest region accounting for around 19% market share. frica was the smallest region accounting for around 2% market share.

Respiratory Drugs Market Global Briefing 2018 provides strategists, marketers and senior management with the critical information they need to assess the global respiratory drugs sector.

Reasons to Purchase:
  • Fully updated for 2018.
  • Identify growth segments and opportunities.
  • Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
  • Develop strategies based on likely future developments.
  • Gain a global perspective on the development of the market.
Description

Respiratory Drugs Market Global Briefing 2018 covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The market characteristics section of the report defines and explains the market.

The market size section gives the respiratory drugs market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the respiratory drugs market and suggests approaches.

Scope:

Markets Covered: Anti-Asthmatics and COPD Drugs, Cough and Cold Preparations.
Companies Mentioned: GlaxosmithKline Plc., AstraZeneca Plc., Merck & Co., Novartis AG, Johnson & Johnson, Gilead, Bayer AG, Boehringer Ingelheim GmbH, Teva Pharmaceuticals, Pfizer Inc.
Geographic Scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa
Time Series: Five years historic and forecast.
Data: Market value in $ billions.
Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Gilead
  • GlaxosmithKline Plc.
  • Johnson & Johnson
  • MORE
Respiratory Drugs Market Characteristics
Respiratory Drugs Market Historic Growth (2013 - 2017)
Respiratory Drugs Market Forecast Growth (2017 - 2021)
Respiratory Drugs Market Segmentation
Global Respiratory Drugs Market, Split by Segments, 2017, $ Billion
Anti-Asthmatics and COPD Drugs
Cough and Cold Preparations
Global Respiratory Drugs Market, Historic and Forecast, Split by Segments, 2013 - 2021
Respiratory Drugs Market Geography Regional and Country Comparison
Global Respiratory Drugs Market, Split by Regions, 2017
Global Respiratory Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Global Respiratory Drugs Market, Split by Country, 2017
Global Respiratory Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Respiratory Drugs Market Competitive Landscape
GlaxosmithKline Plc
AstraZeneca Plc
Merck & Co
Novartis AG
Johnson & Johnson
Gilead
Bayer AG
Boehringer Ingelheim GmbH
Teva Pharmaceuticals
Pfizer Inc
GlaxoSmithKline
AstraZeneca PLC
Merck & Co
Respiratory Drugs Market Key Mergers and Acquisitions
AstraZeneca Acquired Almirall’s Respiratory Business
Recordati Acquired Italchimici S.p.A
Mast Therapeutics, Inc. Merged With Savara
Vectura Merged With Skyepharma
Ruthigen Merged With Pulmatrix
Ario Pharma Acquired PharmEste’s TRPA1 Research Assets
Respiratory Drugs Market Trends and Strategies
Growing Demand For Tamper-Resistant Pseudoephedrine (PSE) Products
Resurgence of Nasal Remedies For Treatment of Cold
Development of RMC-1 Drug For Respiratory Diseases Treatment
Collaborations in the Respiratory Diseases Drugs Market
Appendix
NAICS Definitions of Industry Covered in This Report
Definition of Market Covered in This Report
Abbreviations
Currencies
Research Methodology
Research Inquiries
About the Publisher

List of Figures
Figure 1: Global Respiratory Drugs Market, Historic Market Size, 2013 - 2017, $ Billion
Figure 2: Global Respiratory Drugs Market, Forecast Market Size, 2017 - 2021, $ Billion
Figure 3: Global Respiratory Drugs Market, Split by Segments, 2017, $ Billion
Figure 4: Global Respiratory Drugs Market, Historic and Forecast, Split by Segment, 2013 - 2021
Figure 5: Global Respiratory Drugs Market, Split by Region, 2017, $ Billion
Figure 6: Global Respiratory Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Figure 7: Global Respiratory Drugs Market, Split by Country, 2017 $ Billion
Figure 8: Global Respiratory Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Figure 9: Global Respiratory Drugs Market, Key Competitor Estimated Market Shares, 2017, Percentage (%)

List of Tables
Table 1: Global Respiratory Drugs Market, Historic Market Size, 2013 - 2017, $ Billion
Table 2: Global Respiratory Drugs Market, Forecast Market Size, 2017 - 2021, $ Billion
Table 3: Global Respiratory Drugs Market, Split by Segments, 2017, $ Billion
Table 4: Global Respiratory Drugs Market, Historic and Forecast, Split by Segment, 2013 - 2021
Table 5: Global Respiratory Drugs Market, Split by Region, 2017, $ Billion
Table 6: Global Respiratory Drugs Market, Historic and Forecast Growth Rate, Split by Region, 2013 - 2021
Table 7: Global Respiratory Drugs Market, Split by Country, 2017, $ Billion
Table 8: Global Respiratory Drugs Market, Historic and Forecast Growth Rate, Split by Country, 2013 - 2021
Table 9: Global Respiratory Drugs Market, Key Competitor Estimated Market Shares, 2017, Percentage (%)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AstraZeneca Plc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Gilead
  • GlaxosmithKline Plc.
  • Johnson & Johnson
  • MORE
Respiratory diseases drugs market covers drugs that are used in the treatment of a wide range of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic and acute bronchitis, emphysema and cystic fibrosis. Some of the major drugs in the market include antimuscarinics, corticosteroids, Codral®, Coldrex® and Lemsip®. The market numbers in this briefing cover pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.

North America was the largest region in the respiratory diseases drugs market in 2017, accounting for around 48% market share. This was mainly due to high number of patients with respiratory diseases, more people covered under medical insurance programs and higher pricing of medications in the USA. Asia Pacific was the second largest region accounting for around 19% market share. This can be attributed to the rise in tobacco smoking and pollution levels in Asian countries such as China, India and Japan, thus leading to more number of patients with respiratory diseases. China was the largest, while Japan was the third largest tobacco consuming country in the world. Africa was the smallest region accounting for around 2% market share.

Growing Demand for Tamper-Resistant Pseudoephedrine (PSE) Products - The demand for PSE-containing cold, allergy, and sinus products is growing due to their effectiveness and convenience. PSE is an active ingredient found in various cold, allergy, and sinus drugs that can provide congestion relief. However, PSE-containing medicines are mostly sold as a prescription drug, as PSE can also be used for the illegal manufacture of methamphetamine, a recreational drug. This has led drug manufacturers to produce tamper-resistant PSE products. for instance, in March 2017, pharmaceutical companies Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC entered into an agreement, enabling MainPointe Pharmaceuticals LLC to market NEXAFED and NEXAFED Sinus products in the US and Canada. These drugs utilize tamper-resistant PSE formulation to prevent the illicit production of methamphetamine.
Note: Product cover images may vary from those shown
5 of 5
  • GlaxosmithKline Plc.
  • AstraZeneca Plc.
  • Merck & Co.
  • Novartis AG
  • Johnson & Johnson
  • Gilead
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Teva Pharmaceuticals
  • Pfizer Inc
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll